ArticleEndocrinology, diabetes & metabolism case reports2025
Pre-gestational diabetes in a young woman with a pathogenic INSR missense mutation, p.(Met1180Lys).
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antenatal management ofJCEM case reports · 2026Article
- A Case Report: Treatment, follow-up, and literature review of type A insulin resistance syndrome caused by aFrontiers in endocrinology · 2026Review
- Hyperinsulinemic hypoglycemia due to pathogenic INSR variants: metabolic signature, phenotypic overlap, and semidominant inheritance.Frontiers in endocrinology · 2026Article
- Two Cases of Severe Insulin Resistance in Pregnancy: A New Diagnosis ofJCEM case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: Heterozygous insulin receptor (INSR) mutations cause type A insulin resistance (IR), associated with a phenotype of IR; hyperandrogenism, oligomenorrhoea and acanthosis nigricans in the absence of obesity or lipoatrophy. The phenotype is variable, ranging from neonatal hyperinsulinaemic hypoglycaemia to fasting or post-prandial hypoglycaemia in adults to diabetes. We report a 29-year-old woman presenting at 13 weeks gestation in her second pregnancy. Diabetes was diagnosed at 13-years-old following presentation with lethargy and polyuria and she was treated with metformin 500 mg po bd. She also had polycystic ovarian syndrome, hypothyroidism and epilepsy. Metformin was changed to insulin with good glycaemic control throughout pregnancy. She delivered a 3.95 kg male infant at 39 weeks gestation without neonatal hypoglycaemia. At 18 months post-partum, her body mass index was 26.3 kg/m2, with no evidence of acanthosis nigricans or features of lipodystrophy. As her sister was also diagnosed with diabetes at 13-years-old, next-generation sequencing was performed for known maturity onset diabetes of the young (MODY) genes and a p.(Met1180Lys) mutation in the INSR gene was detected. She reported nocturnal hypoglycaemia and a 5-h oral glucose tolerance test revealed post-prandial hyperinsulinaemic hypoglycaemia at 210 min. Her subsequent pregnancy was spontaneously treated with metformin 500 mg po od from 8 to 25 weeks gestation and discontinued due to intrauterine growth restriction. She delivered a 1.8 kg female infant at 34 plus 3 weeks gestation (25th centile) via elective caesarean section. The infant had transient neonatal hypoglycaemia for two days. Post-partum, she remains diet controlled, with a haemoglobin A1c of 32 mmol/mol. This case highlights the importance of genetic testing to establish optimal diabetes treatment. Learning points: This case highlights the less severe phenotype of IR in a subject with an INSR p.Met1180Lys mutation. It demonstrates the existence of symptomatic post-prandial hypoglycaemia in an adult subject associated with hyperinsulinaemia. This case highlights the importance of genetic testing to establish diagnosis and allows for precision medicine. The role of metformin use in Type A-IR and pregnancy needs to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.